Share capital [Text Block] | 7. Share capital Authorized: unlimited common shares, no par value Ascribed value Number of shares $ November 30, 2015 104,796,421 136,040 Exercise of options 162,854 65 Restricted Share Units 108,399 34 Deferred Share Units 218,795 218 November 30, 2016 105,286,469 136,357 Exercise of options 24,594 9 Restricted Share Units 209,198 83 February 28, 2017, issued and outstanding 105,520,261 136,449 On April 30, 2012, under the NovaGold Arrangement, Trilogy committed to issue up to 6,181,352 20,685 3,447 66,664 (a) Stock options During the period ended February 28, 2017, 1,595,000 1,785,000 0.70 0.44 0.22 For the period ended February 28, 2017, Trilogy recognized a stock-based compensation charge of $ 0.22 0.18 The fair value of the stock options recognized in the period has been estimated using the Black-Scholes option pricing model. Assumptions used in the pricing model for the period are as provided below. February 28, 2017 Risk-free interest rates 0.91 % Exercise price CDN$0.70 Expected life 3.0 years Expected volatility 74.2 % Expected dividends Nil As of February 28, 2017, there were 1,425,009 0.44 0.2 February 28, 2017 Weighted average exercise Number of options $ Balance beginning of period 6,049,433 0.50 Granted 1,595,000 0.53 Exercised (71,666) 0.34 Forfeited (63,335) 0.35 Balance end of period 7,509,432 0.52 Outstanding Exercisable Unvested Weighted average exercise price Weighted average exercise price Range of price Number of outstanding options Weighted average years to expiry $ Number of exercisable options $ Number of unvested options $0.33 to $0.50 4,564,432 3.46 0.39 3,852,762 0.39 711,670 $0.51 to $1.00 2,890,000 3.78 0.70 2,176,661 0.76 713,339 $1.01 to $1.49 55,000 1.17 1.49 55,000 1.49 - 7,509,432 3.57 0.52 6,084,423 0.53 1,425,009 The aggregate intrinsic value of vested share options (the market value less the exercise price) at February 28, 2017 was $ 0.2 0.01 0.01 (b) NovaGold Arrangement Options Under the NovaGold Arrangement, holders of NovaGold stock options received one option in Trilogy for every six options held in NovaGold (“NovaGold Arrangement Options”). All NovaGold Arrangement Options are vested and subject to NovaGold’s stock option plan. The options were fully expensed during the year ended November 30, 2014 and no further expense is recognized. February 28, 2017 Weighted average exercise price Number of options $ Balance beginning of period 312,195 4.28 Expired (245,531) 4.45 Balance end of period 66,664 3.83 Outstanding and exercisable Weighted average exercise price Range of price Number of outstanding options Weighted average years to expiry $ $2.78 to $3.99 49,998 0.08 2.94 $4.00 to $5.99 - - - $6.00 to $6.48 16,666 0.25 6.51 66,664 0.12 3.83 The aggregate intrinsic value of vested NovaGold Arrangement Options (the market value less the exercise price) at February 28, 2017 was $nil (February 29, 2016 - $nil). (c) Restricted Share Units and Deferred Share Units The Company has a Restricted Share Unit Plan (“RSU Plan”) and a Non-Executive Director Deferred Share Unit Plan (“DSU Plan”) to provide long-term incentives to employees, officers and directors. The RSU Plan and DSU Plan may be settled in cash and/or Common Shares at the Company’s election with each RSU and DSU entitling the holder to receive one common share of the Company or equivalent value. All units are accounted for as equity-settled awards. Number of RSUs Number of DSUs Balance beginning of period 400,001 925,390 Granted 600,000 33,258 Vested/paid (399,999) - Balance end of period 600,002 958,648 For the three months ended February 28, 2017, Trilogy recognized a stock-based compensation charge of $ 0.17 0.10 On December 15, 2016, 600,000 399,999 209,198 90,000 (d) Share Purchase Warrants Weighted average exercise price Number of Warrants Weighted average years to expiry $ Balance beginning of period 6,521,740 2.60 1.60 Balance end of period 6,521,740 2.60 1.60 |